In a letter dated July 29, SAMHSA says it will no longer fund “harm reduction” activities it describes as incompatible with federal law and inconsistent with Administration priorities. The letter draws distinction between harm reduction and opioid overdose reversal medications and included guidance on what supplies and services will continue to be funded. AAPP will continue to support funding, access, and delivery of evidence-based harm reduction services to prevent substance-use related injury, disease, overdose, and misuse.